Join to access to all OVN content. Join for Free
The Strategic vs the Scientific MSL
Medical Science Liaisons MSL communication strategic advisers soft skills development active listening healthcare ecosystem challenges AI impact on MSLs

The Strategic vs the Scientific MSL


Share This Article


Summary

In this episode, Tom Caravela is joined by Joy Morrell to explore the multifaceted role of Medical Science Liaisons (MSLs) in medical affairs. They discuss the critical importance of dialogue over monologue in MSL communication, emphasizing the need for both scientific expertise and soft skills development. Joy highlights the significance of active listening and posing key questions to enhance engagement. The conversation shifts to MSLs as strategic advisers and the importance of ongoing training for excellence. They share insights on cultivating a high-performance MSL team and offer tips for strategic growth, while also considering the future impact of AI on the profession. The episode concludes with final advice for aspiring MSLs and leaders.

Key Points

  • MSLs must transition from merely sharing scientific data to providing strategic value by understanding and addressing broader healthcare ecosystem challenges. Active listening and engaging in meaningful dialogue with stakeholders are crucial skills that MSLs need to cultivate to be more effective. Organizations should focus on developing MSLs' human skills, such as emotional intelligence and strategic thinking, through intentional training and mentorship.

Click for Source
Medical Science Liaisons, MSL communication, strategic advisers, soft skills development, active listening, healthcare ecosystem challenges, AI impact on MSLs

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
How to Start Presenting Like a Pro
Partner Avatar MSL Talk: Tom Caravela

How to Start Presenting Like a Pro

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Article
Clinical Educator Oncology Program Improves Adherence by 29%​
Partner Avatar iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%​

Explore OVN